There has been recent interest in the use of cognitive enhancing drugs, such as cholinesterase inhibitors, as a possible treatment for executive functioning (EF) deficits in autism spectrum disorder (ASD). The goal of this study was to assess the tolerability, safety, and efficacy of donepezil on EF in a sample of children and adolescents with ASD.
Method:
Thirty-four children and adolescents with ASD (age range 8–17 years; IQ >75) were enrolled in a 10-week, double-blind, placebo-controlled trial of donepezil (doses of 5 and 10 mg), followed by a 10-week open label trial for placebo nonresponders.
Results:
The effect of donepezil treatment on EF was examined. Despite improvement on a number of EF measures, no statistically significant between-group differences were found (with gains observed for both the placebo and donepezil groups).
Conclusions:
The results suggest that short-term treatment with donepezil may have limited impact on cognitive functioning in ASD. Future controlled trials may need to consider a longer treatment period to detect significant gains on EF measures.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed text revision. (DSM-IV-TR)Washington, DC: American Psychiatric Association, 2000.
2.
BaumanML, KemperTL. Neuroanatomic observations of the brain in autism. The Neurobiology of Autism. BaumanM., KemperT.Baltimore, MD: The Johns Hopkins University Press, 1994; 119–145.
3.
BrownellR. The Expressive One-Word Vocabulary Test. East Moline, IL: LinguiSystems, Inc., 2000.
4.
BuschkeH, FuldPA. Evaluating storage, retention, and retrieval in disorder memory and learning. Neurology, 24:1019–1025. 1974.
5.
Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States, 2002, Autism, Developmental Disabilities Monitoring Network Surveillance Year, Principal Investigators, Centers for Disease Control and Prevention. MMWR Surveill Summ, 56:12–28. 2007.
6.
ChezMG, AimonovitchM, BuchananT, MrazekS, TrembRJ. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol, 19:165–169. 2004.
7.
ChezMG, BuchananTM, BeckerM, KesslerJ, AimonovitchMC, MrazekSR. Donepezil hydrochloride: A double-blind study in autistic children. J Pediatr Neurol, 1:83–88. 2003.
8.
DelisC, KaplanE, KramerJH. Delis-Kaplan Executive Function System: Technical Manual. San Antonio, TX: The Psychological Corporation, 2001.
9.
DelisDC, KramerJH, KaplanE, OberBA. California Verbal Learning Test-Children's Version: Manual. San Antonio, TX: The Psychological Corporation, 1994.
10.
FombonneE. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry, 10:3–8. 2005.
11.
HandenBL, JohnsonCR, McAuliffe-BellinSJ, HardanAO. Safety and efficacy of Donepezil in children and adolescents with autism: Behavioral measures. Int J Child Adolesc Health(In press).
12.
HandenBL, LubetskyMJ. Psychopharmacology in autism. School Psych Q, 20:155–171. 2005.
13.
HandenBL, MelmedRD, HansenRL, AmanMG, BurnhamDL, BrussJB, McDougleCJ. A double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. J Autism Dev Disord, 39:796–805. 2009.
14.
HardanAY, HandenBL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol, 12:237–241. 2002.
15.
HertzmanM. Galantamine in the treatment of adult autism: A report of three clinical cases. Int J Psychiatry Med, 33:395–398. 2003.
16.
HohmannC, Berger-SweeneyJ. Cholinergic regulation of cortical development and plasticity: New twists to an old story. Perspect Dev Neurobiol, 5:401–425. 1998.
17.
JustM, CherasskyV, KellerT, KanaR, MinshewN. Functional and anatomical cortical underconnectivity in autism: Evidence from an fMRI study of an executive function task and corpus callosum morphometry. Cereb Cortex, 17:951–961. 2007.
18.
KingBH, HollanderE, SikichL, McCrackenJT, ScahillL, BregmanJD, DonnellyCL, AnagnostouE, DukesK, SullivanL, HirtzD, WagnerA, RitzL. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry, 66:583–590. 2009.
19.
LeeM, Martin-RuizC, GrahamA, CourtJ, JarosE, PerryR, IversenP, BaumanM, PerryE. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain, 125:1483–1495. 2002.
20.
LordC, RutterM, DiLavorePC, RisiS. Autism Diagnostic Observation Schedule: A Standardized Observation of Communicative and Social Behavior. Los Angeles, CA: Western Psychological Services, 1999.
21.
MinshewN, GoldsteinG, SiegelD. Speech and language in high functioning autistic individuals. Neuropsychology, 9:255–261. 1995.
22.
MinshewN, JohnsonCR, LunaB. The cognitive, neural basis of autism: A disorder of complex information processing, dysfunction of neocortical systems. International Review of Research in Mental Retardation. GliddenL.M.New York: Academic Press, 2000; 111–138.
23.
MinshewN, SiegelD, GoldsteinG, WeldyS. Verbal problem solving in high functioning autistic individuals. Arch Clin Neuropsychol, 9:31–40. 1994.
24.
NicholsonR, Craven-ThussB, SmithJJ. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol, 16:621–629. 2006.
25.
NiederhoferH, StaffenW, MairA. Galantamine may be effective in treating autistic disorder. Br J Med, 325:1422. 2002.
26.
OzonoffS, McEnvoyRE. A longitudinal study of executive function and theory of mind development in autism. Dev Psychopathol, 6:415–431. 1994.
27.
PerryE, LeeM, Martin-RuizC, CourtJ, VolsenSG, MerritJ, FollyE, IversenP, BaumanM, PerryR, WenkGL. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry, 158:1058–1066. 2001.
28.
RajendranG, MitchellP. Cognitive theories of autism. Dev Rev, 27:224–260. 2007.
29.
ReichW, WelnerZ, HerjanicB. MHS Staff: Manual for the Diagnostic Interview for Children & Adolescents-IV (DICA-IV)North Tonawanda, NY: Multi-Health System, Inc., 1997.
30.
RussellJ. Autism as an Executive Disorder. New York: Oxford University Press, 1997.
31.
RutterM, Le CouteurA, LordC. Autism Diagnostic Interview-Revised. Los Angeles, CA: Western Psychological Services, 2003.
32.
SohlbergMM, MateerCA. Introduction to Cognitive Rehabilitation: Theory, Practice. New York: Guilford Press, 1989.
WechslerD. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation, 1999.
35.
WelshMC, PenningtonBF. Assessing frontal lobe functioning in children: Views from developmental psychology. Dev Neuropsychol, 4:199–230. 1988.
36.
YooHJ, ValdovinosHG, WilliamsDC. Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature. J Autism Dev Disord, 37:1883–1901. 2007.
